2. Academic Validation
  3. Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH Treatments

Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH Treatments

  • J Med Chem. 2025 Mar 27;68(6):6815-6831. doi: 10.1021/acs.jmedchem.5c00301.
Maria-Eleni Kouridaki 1,  Jonathan Gillespie 2,  John Robinson 2,  Tanya Mathie 2,  Laura Bain 2,  Duncan McArthur 2,  Angus Morrison 2,  Daniel B Greenslade 1,  Michail Papadourakis 1,  Kasia Maj 3,  Kate Cameron 3,  Darryl Turner 4,  Scott P Webster 5,  Martin A Wear 6,  Dahlia Doughty-Shenton 7,  Alison N Hulme 1,  Julien Michel 1
Affiliations

Affiliations

  • 1 EaStCHEM School of Chemistry, University of Edinburgh, David Brewster Road, Edinburgh, Scotland EH9 3FJ, U.K.
  • 2 BioAscent Discovery Ltd., Newhouse, Scotland Lanarkshire ML1 5UH, U.K.
  • 3 Cytochroma Ltd., Roslin Innovation Centre, Easter Bush Estate, Edinburgh, Scotland EH25 9RG, U.K.
  • 4 Concept Life Sciences Ltd., Nine, 9 Little France Road, Edinburgh Bioquarter, Edinburgh, Scotland EH16 4UX, U.K.
  • 5 Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, Scotland EH16 4TJ, U.K.
  • 6 The Edinburgh Protein Production Facility (EPPF), University of Edinburgh, Level 3 Michael Swann Building, King's Buildings, Max Born Crescent, Edinburgh, Scotland EH9 3FF, U.K.
  • 7 Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, 4-5 Little France Drive, Edinburgh Bioquarter, Edinburgh, Scotland EH16 4UU, U.K.
PMID: 40074291 DOI: 10.1021/acs.jmedchem.5c00301
Abstract

Cyclophilins have been implicated in the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH). Pharmacological inhibition of the Cyclophilin B isoform has the potential to attenuate liver fibrosis in MASH, but current Cyclophilin inhibitors in clinical trials lack isoform selectivity. We previously reported the novel tri-vector small-molecule inhibitor 1 that exhibited improved subtype selectivity by simultaneously engaging three pockets on the surface of cyclophilins. Here, we present structure-activity relationships that address genotoxicity concerns, enhance subtype selectivity, improve pharmaceutical properties, and demonstrate strong efficacy in a MASH cellular model. Lead compound 11 is a potent Cyclophilin B Inhibitor with an encouraging pharmacokinetic profile suitable for further development.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z